Organogenesis (NASDAQ:ORGO) Given New $8.00 Price Target at BTIG Research

Organogenesis (NASDAQ:ORGO) had its price target reduced by BTIG Research from $9.00 to $8.00 in a report released on Friday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other research analysts have also recently commented on ORGO. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.67.

Organogenesis Stock Performance

ORGO stock traded down $0.49 during midday trading on Friday, hitting $3.21. The stock had a trading volume of 1,686,783 shares, compared to its average volume of 520,021. Organogenesis has a 52 week low of $2.61 and a 52 week high of $7.08. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $4.23 and a 200 day simple moving average of $4.59. The firm has a market capitalization of $407.38 million, a price-to-earnings ratio of 40.13 and a beta of 1.46.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 22.64%. The company had revenue of $225.61 million during the quarter, compared to analysts’ expectations of $172.68 million. As a group, equities research analysts anticipate that Organogenesis will post -0.07 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the sale, the director directly owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This trade represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 33.00% of the stock is owned by corporate insiders.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Quarry LP acquired a new position in Organogenesis during the 3rd quarter worth about $25,000. State of Alaska Department of Revenue acquired a new position in shares of Organogenesis during the third quarter worth approximately $25,000. Flagship Harbor Advisors LLC bought a new stake in shares of Organogenesis during the fourth quarter valued at approximately $34,000. Federated Hermes Inc. increased its holdings in shares of Organogenesis by 52.8% in the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after purchasing an additional 2,953 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in shares of Organogenesis in the fourth quarter valued at approximately $57,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

More Organogenesis News

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Record Q4 results — Organogenesis reported Q4 revenue of $225.6M (big beat) and EPS that topped estimates, with strong gross‑profit and operating‑profit expansion and materially higher operating cash flow. This explains recent upside in sentiment from the quarter’s beat. Organogenesis Reports Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Analyst price‑target adjustment — BTIG trimmed its target from $9.00 to $8.00 but maintained a Buy rating, still implying substantial upside from today’s price. This keeps some analyst support but signals more cautious optimism. BTIG Price Target Update via Benzinga
• Negative Sentiment: Weak FY‑2026 guidance — management issued revenue guidance of $350M–$420M for FY‑2026, well below consensus (~$543M). The large gap between the outlook and street expectations is the primary driver of the stock weakening today. FY‑2026 Guidance and Earnings Release (MarketBeat)
• Negative Sentiment: Insider and institutional flows — notable insider selling (reported large insider sales) and mixed institutional activity (some large redemptions/position cuts) may add selling pressure or indicate some investors are booking gains after the strong quarter. QuiverQuant Coverage of Q4 Results & Insider Activity

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.